

Eisai Co Ltd (4523) - Financial and Strategic SWOT Analysis Review

URL:	https://marketpublishers.com/r/EA84063DD6AEN.html
Date:	July 18, 2017
Pages:	57
Price:	US\$ 125.00
ID:	EA84063DD6AEN

Eisai Co Ltd (4523) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company's operations and business divisions.
- Corporate strategy – Analyst's summarization of the company's business strategy.
- SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives' employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Eisai Co Ltd (Eisai) is a pharmaceutical company that undertakes the research, development, manufacture and marketing of pharmaceuticals, including over-the-counter (OTC) drugs, prescription medicines and generics. The company's franchise areas in research include neurology and oncology. Eisai's major products include Pariet/AcipHex (proton pump inhibitor); Aricept, an anti-Alzheimer's agent; Halaven, a novel anti-cancer agent; Fycompa, an anti-epileptic and peripheral neuropathy treatment, among others. Eisai has production plants in Japan, the UK, China and India and laboratories in Japan, the US and the UK; overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.

Eisai Co Ltd Key Recent Developments

Jul 03,2017: Wellness Open Living Labs, Co-Founded by Eisai and Osaka City University Conclude Basic Collaboration Agreement Aimed at Solving Health Problems

Jun 28,2017: Eisai Listed for 16th Consecutive Year in FTSE4Good Index Series, an Index for Socially

Responsible Investment

Jun 01,2017: Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria

Jun 01,2017: Eisai Commits Funding to the 2nd Phase of Global Health Innovative Technology Fund Activities

May 10,2017: Eisai: Proposed Changes in Representative Officers

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Content

SECTION 1 - ABOUT THE COMPANY

Eisai Co Ltd - Key Facts

Eisai Co Ltd - Key Employees

Eisai Co Ltd - Key Employee Biographies

Eisai Co Ltd - Major Products and Services

Eisai Co Ltd - History

Eisai Co Ltd - Company Statement

Eisai Co Ltd - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Joint Venture

SECTION 2 – COMPANY ANALYSIS

Eisai Co Ltd - Business Description
Eisai Co Ltd - Corporate Strategy
Eisai Co Ltd - SWOT Analysis
SWOT Analysis - Overview
Eisai Co Ltd - Strengths
Eisai Co Ltd - Weaknesses
Eisai Co Ltd - Opportunities
Eisai Co Ltd - Threats
Eisai Co Ltd - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Eisai Co Ltd, Recent Deals Summary

SECTION 5 – COMPANY'S RECENT DEVELOPMENTS

Jul 03, 2017: Wellness Open Living Labs, Co-Founded by Eisai and Osaka City University Conclude Basic Collaboration Agreement Aimed at Solving Health Problems
Jun 28, 2017: Eisai Listed for 16th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment
May 10, 2017: Eisai: Proposed Changes in Representative Officers
Apr 19, 2017: Eisai Announces Results and Continued Support of Initiatives for Elimination of Lymphatic Filariasis
Mar 09, 2017: Results from Studies using PXB-Mouse being presented at ToxExpo 2017
Jan 18, 2017: Eisai To Participate In Access Accelerated, Global Partnership To Address Rise Of Non-Communicable Diseases
Jan 12, 2017: Eisai To Launch Medication Administration Support Device e-OKUSURI-SAN
Aug 23, 2016: EISAI To Launch Chocolate BB Mouth Ulcer Repair Shot
Jul 11, 2016: NTT IT, NTT East and Eisai Rollout Interprofessional Collaboration Business for Medical Treatment and Care
Jun 30, 2016: Eisai Listed For 15th Consecutive Year In FTSE4Good Index Series, An Index For Socially Responsible Investment

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Eisai Co Ltd, Key Facts
Eisai Co Ltd, Key Employees
Eisai Co Ltd, Key Employee Biographies
Eisai Co Ltd, Major Products and Services
Eisai Co Ltd, History
Eisai Co Ltd, Subsidiaries
Eisai Co Ltd, Joint Venture
Eisai Co Ltd, Key Competitors
Eisai Co Ltd, Ratios based on current share price
Eisai Co Ltd, Annual Ratios
Eisai Co Ltd, Annual Ratios (Cont...1)
Eisai Co Ltd, Annual Ratios (Cont...2)
Eisai Co Ltd, Interim Ratios
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Eisai Co Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Eisai Co Ltd, Performance Chart (2013 - 2017)
Eisai Co Ltd, Ratio Charts
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

Takeda Pharmaceutical Company Ltd
Ono Pharmaceutical Co Ltd
Nippon Kayaku Co Ltd
Mochida Pharmaceutical Co Ltd
Daiichi Sankyo Inc
Chugai Pharmaceutical Co Ltd
Astellas Pharma Inc

I would like to order:

Product name: Eisai Co Ltd (4523) - Financial and Strategic SWOT Analysis Review
Product link: <https://marketpublishers.com/r/EA84063DD6AEN.html>
Product ID: EA84063DD6AEN
Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/EA84063DD6AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
E-mail:
Company:
Address:
City:
Zip/Post Code:
Country:
Tel:
Fax:
Your message:

* All fields are required

Customer Signature _____

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms_conditions.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**